Current status of radiofrequency ablation of hepatocellular carcinoma

Table 1 Summary of therapeutic results of 6 large series cohort studies with percutaneous RFA alone

Year	Author	PatientNo.	Size (cm)1	FU (mo)2	LTP (%)3	New recur (%)4	Major Cx (%)5	Overall survival (%)			Median survival(mo)	Evidence6
								1 yr	3 yr	5 yr
2005	Lencioni et al[13]	206	< 5	24	10	49	2.0	97	67	41	57	2
2005	Tateishi et al[14]	319	< 5	28	8.7	60	4.0	95	78	54	NA	2
2005	Chen et al[15]	256	< 8	2-69	NA	NA	2.4	83	67	41	NA	2
2007	Choi et al[16]	570	< 5	30	11.8	52	1.9	95	70	58	77	2
2008	Livraghi et al[17]	216	< 2	31	0.9	NA	1.8	NA	76	55	NA	2
2009	N'Kontchou et al[18]	235	< 5	27	11.5	42	0.9	NA	60	40	48

RFA: Radiofrequency ablation;

¹Maximum diameter of tumor;

²Mean follow-up period;

³Rate of local tumor progression;

⁴Rate of new recurrence including intrahepatic remote and extrahepatic metastasis;

⁵Rate of major complications requiring additional hospitalization or therapeutic procedure;

⁶Level of evidence.